Clinical Observation of Zhenqi Fuzheng Granule Combined with Dasatinib in the Treatment of BCR-ABL Positive Leukemia / 中国药房

ABSTRACT

OBJECTIVE:To observe the efficacy and safety of Zhenqi fuzheng granule combined with dasatinib in the treat-ment of BCR/ABL positive leukemia. METHODS:40 patients with BCR-ABL positive chronic myeloid leukemia or PH-positive acute lymphoblastic leukemia were randomly divided into control group(20 cases)and observation group(20 cases). Control group received Dasatinib tablet,CML patients in chronic period received 100 mg,once a day,orally,morning or evening;CML patients in acceleration period and blastic period received 140 mg,once a day,orally,morning or evening,swallow whole,no cut or crushed. Observation group additionally received 15 g of Zhenqi fuzheng granule,twice a day. The treatment course for both groups was 24 months. Hematologic response,cytogenetic response and molecular biological response in 2 groups were observed, fatality rate,mean follow-up time and the incidence of adverse reactions were followed-up. RESULTS:CCR in observation group was significantly higher than control group,mean follow-up time was longer than control group,CCR median time was significant-ly shorter than control group,the incidence of adverse reactions and fatality rate were significantly lower than control group,the differences were statistically significant(P0.05). CONCLUSIONS:Zhenqi fuzheng granule combined with dasatinib is superior to dasat-inib alone in proving hematologic response and safety in the treatment of BCR-ABL positive leukemia,and similar in cytogenetic response and molecular biological response.